Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany.

ABSTRACT:

Purpose

Bisphosphonates and denosumab prevent bone complications in patients with bone metastases from solid tumours. This retrospective, longitudinal, cohort study provides data on their real-world use in this setting in Germany.

Methods

Adults with bone metastases from breast, prostate or lung cancer who were newly initiated on a bisphosphonate or denosumab between 1 July 2011 and 31 December 2015 were identified from a German healthcare insurance claims database. Primary outcomes included persistence, compliance, discontinuation and switch rates at 12 months.

Results

This study included 1130 patients with bone metastases: 555 (49%) had breast cancer, 361 (32%) prostate cancer and 242 (21%) lung cancer. Mean age was 65 years for patients with breast or lung cancer a

SUBMITTER: Diel I 

PROVIDER: S-EPMC7547046 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature